IART vs JNJ vs HOLX vs SYK

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate Integra LifeSciences Holdings Corporation (IART) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hologic, Inc.

(HOLX) is the cheapest at 30. 5x versus Johnson & Johnson at 38. 4x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Johnson & Johnson's 34. 17x — a reasonable growth-adjusted valuation.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +46.

1%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: SYK returned +187. 1% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 4001% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: Stryker Corporation grew EPS 8. 2% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus 4. 2% for IART. At the gross margin level — before operating expenses — JNJ leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Johnson & Johnson's 34. 17x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5. 8x forward P/E versus 19. 6x for Stryker Corporation — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 37. 2% to $403. 69.

In this comparison, JNJ (2.

2% yield), SYK (1. 1% yield) pay a dividend. IART, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

JNJ, SYK pay a dividend while IART, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.